On 4/19/2017, Shares of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) closed at $6.48 in last trading day. After noting the initial trading entry at $6.44, it reached to a day’s high of $6.52 and moved to a day’s low of $6.36. The recent daily volume was 474.95 thousand as contrast to it’s an average volume of 745.28 thousand.
The last close of the Spectrum Pharmaceuticals, Inc. stock reflects that it traded up +1.03% from its 50-day moving average of $6.41. The stock traded above +29.29% to its 200-day MA of $5.01. Furthermore, it moved lower -16.28% from its 52-week high of $7.74 and +101.87% up from $3.21, which is 52-week low of the stock.
During the last month, Spectrum Pharmaceuticals, Inc.’s (SPPI) has changed -0.46% and performed 62.41% over the last 6 months. The mean rating score for this stock is at 1.30. This rating scale contains from 1 to 5 with 5 representing a Strong Sell, 1 signifying a Strong Buy and 3 demonstrating a Hold. The Volatility was noted at 3.67% in recent month and observed Weekly Volatility of 2.97%.
Spectrum Pharmaceuticals, Inc. develops and commercializes oncology and hematology drug products. The company markets six drug products, including FUSILEV for patients with metastatic colorectal cancer and rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor to treat patients with relapsed or refractory PTCL; ZEVALIN injection for patients with follicular non-Hodgkin’s lymphoma; MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ injection for patients with relapsed or refractory PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients. It is also developing ROLONTIS for chemotherapy-induced neutropenia; QAPZOLA for intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer; and POZIOTINIB for treating breast and lung cancer. The company sells its drugs through a direct sales force in the United States; and through distributors in Europe. Spectrum Pharmaceuticals, Inc. has licensing and development agreement with Cell Therapeutics, Inc.; license agreement with Merck & Cie AG, Sloan-Kettering Institute, and Cydex Pharmaceuticals, Inc.; development and commercialization collaboration agreement with Allergan, Inc.; collaboration agreement with Nippon Kayaku Co., LTD.; licensing and collaboration agreement with Onxeo DK; and co-development and commercialization agreement with Hanmi Pharmaceutical Company. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Henderson, Nevada.
Advanced Energy Industries, Inc. (NASDAQ:AEIS) finalized the last transaction at value of $67.105, with a daily change of +2.061% or +1.355 points. The company maintained volume of 446.9 thousand shares. In past trading day, the stock hit the maximum price of $67.970 and touched to minimum value of $66.215. It has a market cap of $ 2.67B.
As of last trade close, the stock is trading downside -5.004% from its one year high of $70.640 and moved +109.834% upward from $31.980, which is one year low of the stock.
The stock traded above +1.705% from its 50-day moving average of $65.980. Furthermore, the stock moved up +17.026% to its 200-day MA of $ 57.342.
Advanced Energy Industries, Inc.’s (AEIS) moved with shift of 0.98% in the past week. Over the last three months, the shares of the company have changed 17.94% and performed 43.34% over the last six months. The stock currently has Monthly Volatility of 2.55% and Weekly Volatility of 2.14%.
April 17, 2017 Advanced Energy Industries, Inc. (AEIS), a leader in precision power conversion, will release its first quarter financial results after market close on Monday, May 1, 2017. Management’s quarterly conference call will be held on Tuesday, May 2, beginning at 6:30 a.m. Mountain Time / 8:30 a.m. Eastern Time.